Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy is under clinical development by Olagenesis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy’s likelihood of approval (LoA) and phase transition for Dilated Cardiomyopathy took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy overview

Stem cell therapy is under development for the treatment of dilated cardiomyopathy. It is a bone marrow mononuclear cell. It is administrated through intracoronary infusion route. The stem cells obtained from the patient's bone marrow are delivered into the coronary arteries. It was also under the development for the treatment of acute myocardial infarction (heart attack).

Quick View Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy LOA Data

Report Segments
  • Innovator
Drug Name
  • Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy
Administration Pathway
  • Intracoronary
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.